Therefore, we further used flow cytometry to analyze immune cell infiltration in endpoint tumors, indicating that the percentage of CD206+ ST2L+ M2 macrophages, M2/M1 ratio and CD4+ Foxp3+ Tregs were higher in tumor allografts from the cisplatin monotherapy group (Fig. 5E–G). The gene discussed is MRC1; the disease is neoplasm.